640.4 -20.43 (-3.19%) Sell

GLENMARK is a falling knife, continues to bleed every investor trying to catch it

13 min read

GLENMARK ranked among the worst performers today. On a longer term basis, investors in GLENMARK PHARMACEUTICALS made +0.04% per day. Friday's performance of -3.19% was a underperformance compared to it's daily average.

[Themes containing GLENMARK]

GLENMARK showed a bullish trend over the last 3 months. During this period GLENMARK increased by +6.91% and saw a maximum drawdown of -8.35%. There were 2 long signals during this period that returned a cumulative of +2.98% to investors.


GLENMARK has been underperforming the NIFTY-50 index in recent time. It showed significant underperformance (compared to the NIFTY-50 index) from 5 Jan, 2016 to 14 May, 2018. Over the last 3 years and 1 month, GLENMARK underperformed the NIFTY-50 index on 51% days.

During the last three months GLENMARK was mostly profitable and delivered on average +0.12% per day. It's best return during this period (of +4.72%) was on Tuesday, 11 Dec, 2018. While it's worst loss in the same period (of -4.82%) was on Monday, 3 Dec, 2018. The longest stort-term trend during this period was 7 profitable days, which started on 31 Oct, 2018 and went on till 9 Nov, 2018. This bullish trend returned +11.43% to investors.

The last 12 months saw GLENMARK's investors making profits in 6 months and incurring losses in 6 months. During the last year, GLENMARK delivered profits in more months than NIFTY-50 index. GLENMARK significantly outperformed NIFTY-50 index in Aug 2018, when it returned +14.47% compared to +6.56% returned by NIFTY-50 index during it's best month in the last one year - Jul 2018. GLENMARK had a longer winning streak of profitable months than NIFTY-50 index. It went up in 3 straight months (from Jun 2018 to Aug 2018) during which period it delivered +23.49%.

An investment in knowledge pays the best interest.
-- Benjamin Franklin

GLENMARK is currently seeing overall fall in volatility. In comparison, the NIFTY-50 index is seeing decrease in volatility. During the last three months, there was a significant surge in GLENMARK's volatility from 19 Oct, 2018 to 14 Nov, 2018. While there was a significant fall in the NIFTY-50 index's volatility from 31 Oct, 2018 to 5 Dec, 2018.

Advanced/professional short-term investors should note that GLENMARK has significant positive skewness in it's return distribution. This indicates that investors can expect GLENMARK to recover from drawdowns quickly. Which makes GLENMARK a good candidate for investing on short-term bullish trends or even counter-trends hoping for a pull-back.

Investors trading in GLENMARK derivatives at this moment can consider 'Married Call' options strategy to receive better risk-adjusted returns.

NIFTY-50 index has more chance of extreme outcomes than GLENMARK. Therefore, NIFTY-50 must receive a lower allocation than GLENMARK in your portfolio. GLENMARK usually has shorter drawdown period than the NIFTY-50 index.

Based on your interest in GLENMARK you may find it interesting to know that BRITANNIA, ~MKTCAP201TO250 and ~CHEMICALS have all shown remarkable performance and qualify to be on every investor's watchlist.

Want to improve your Portfolio's performance?

Spotalpha's Portfolio optimizer is all you need to improve your returns and reduce your risk.
Optimize Portfolio NOW
If you liked what you read here ...

... we have a small favour to ask. Help us bring the power of algorithmic trading strategies to individual investors.

All content in this article was automatically generated by algorithms. This ensures that there are no human biases in the analysis provided. This approach to investing is not new and has been around for more than three decades. Yet, it has been available to only the most affluent or elite investors leaving individual investors to trade on emotions (such as fear and greed), intuition and poor analysis from third-parties. We want to change this.

We want to empower investors with all the tools and analysis required by them to make a rational investment decision.

If you found Spotalpha useful, consider making a contribution. For as little as $5 you can support our efforts and it takes less than a minute. Thank you. Contribute
Share with friends   WhatsApp   Facebook   Twitter